WO2009045515A2 - Composition antimicrobienne et antivirale - Google Patents

Composition antimicrobienne et antivirale Download PDF

Info

Publication number
WO2009045515A2
WO2009045515A2 PCT/US2008/011473 US2008011473W WO2009045515A2 WO 2009045515 A2 WO2009045515 A2 WO 2009045515A2 US 2008011473 W US2008011473 W US 2008011473W WO 2009045515 A2 WO2009045515 A2 WO 2009045515A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
weight
amount
antimicrobial
recited
Prior art date
Application number
PCT/US2008/011473
Other languages
English (en)
Other versions
WO2009045515A4 (fr
WO2009045515A3 (fr
Inventor
John A. Willimann
William Chandler
Original Assignee
Global Life Technologies Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/906,640 external-priority patent/US20090011042A1/en
Priority claimed from US12/148,967 external-priority patent/US7638147B2/en
Application filed by Global Life Technologies Corp. filed Critical Global Life Technologies Corp.
Publication of WO2009045515A2 publication Critical patent/WO2009045515A2/fr
Publication of WO2009045515A3 publication Critical patent/WO2009045515A3/fr
Publication of WO2009045515A4 publication Critical patent/WO2009045515A4/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto

Definitions

  • This invention relates to antiseptic compositions and, more particularly, to a nasal antiseptic barrier composition having antimicrobial, antiviral, and antifungal properties. Discussion of the Related Art
  • the onset of respiratory disease is primarily a result of inhalation of airborne pathogens through the nose and mouth.
  • the oral cavity is better equipped to kill airborne pathogens before they can enter and infect the body.
  • saliva in the mouth captures many airborne pathogens before they are inhaled into the lungs. Once the saliva containing the pathogens is swallowed, stomach acids are highly effective in killing these pathogens before they can infect the body.
  • the nasal passages are less effective in trapping and killing microorganisms. Airborne pathogens inhaled through the nose usually enter the lungs where there can cause respiratory infection or other types of infection once these pathogens enter the blood stream.
  • Face masks are effective to prevent entry of pathogens into the respiratory system.
  • face masks is generally impractical, inefficient and socially unappealing.
  • NCHS National Center for Health Statistics
  • the present invention is directed to an antimicrobial and antifungal barrier composition for topical application to the proximal anterior nares (rim surrounding the nostrils).
  • the composition includes an antiseptic solution in combination with cocos nucifera (coconut oil) and one or more citrus oils such as, for example, citrus sinensis (orange oil).
  • examples of an antiseptic solution include one or more alcohols, such as ethyl alcohol, or hydrogen peroxide.
  • the composition may include one or more additional ingredients, including: lauric acid; simmondsia chinensis (Jojoba); d-limonene; soy oil; emu oil; grapefruit seed extract; glycine soja; aloe vera and a preservative, such as sodium benzoate, benzalkonium chloride, BHT and vitamin E.
  • additional ingredients including: lauric acid; simmondsia chinensis (Jojoba); d-limonene; soy oil; emu oil; grapefruit seed extract; glycine soja; aloe vera and a preservative, such as sodium benzoate, benzalkonium chloride, BHT and vitamin E.
  • the composition When properly applied to the skin surrounding the nostril openings, the composition has been proven effective in killing 99.99999% (7 log) or greater germs. This extremely efficient antimicrobial efficiency persists for at least 8 hours. Results from laboratory studies have shown efficacy in killing streptococcus (pneumoniae and pyogenes), staphylococcus aureus, mycobacterium smegmatis, and haemophilus influenza bacterias.
  • the antimicrobial and antiviral composition of the present invention was further shown to be effective in eradicating the rhinovirus and influenza A virus (avian flu), as well as the corona virus.
  • the corona virus is known to be the cause of SARS.
  • the composition of the present invention has also been proven to help alleviate the body's immuno-response to many allergens including, but not limited to, dust mites, pollen, hay fever, animal dander, dust, particulate pollution, ozone, sulfur dioxide, and nitrogen oxide.
  • the composition is effective in trapping these allergens and alleviating the body's response to their presence.
  • the composition acts as a barrier in the nose and lessens the IGA response in the body. It is also believed that the composition works to lessen the Interleukin expression in the nose, especially ILB, commonly perspective for the inflammation response in the nasal cavity.
  • a particularly effective formulation includes one or more of the following ingredients in combination with citrus oils, cocos nucifera and glycine soja: beeswax; bees milk; and fruit wax.
  • the present invention is directed to a long lasting antimicrobial and antiviral barrier composition for topical application to the proximal anterior nares (skin surface surrounding the opening of the nostrils).
  • the antimicrobial and antiviral composition of the present invention incorporates the use of one or more antiseptic solutions in combination with cocos nucifera (coconut oil), citrus sinensis (orange oil), and simmondsia chinensis (Jojoba).
  • the antiseptic solution is USP ethyl alcohol.
  • the antiseptic solution is hydrogen peroxide.
  • Other alcohols and antiseptic agents are contemplated for use in the composition as the antiseptic solution, either alone or as a combination.
  • composition The essential ingredients of the composition are present according to the following percentages by weight of the composition:
  • Citrus Sinensis between 0.05% and 60%
  • the antimicrobial and antiviral composition of the present invention may further include the following additional ingredients, alone or in combination: lauric acid; simmondsia chinensis; d-limonene; soy oil; emu oil; grapefruit seed extract; glycine soja; and a preservative such as sodium benzoate, benzalkonium chloride, BHT, vitamin E.
  • additional ingredients of the composition are present according to the following percentages by weight of the composition: Amount
  • Glycine Soja (soy oil) between 0.1% and 80%
  • Emu oil between 0.1% and 10%
  • Grapefruit Seed extract between 0.1% and 8%
  • Benzalkonium Chloride between 0.1% and 5%
  • Vitamin E between 0.1% and 4%
  • composition has been proven to help alleviate the body's immune-response to many allergens and pollutants.
  • the following ingredients have been found to be effective in the composition when present according to the following percentages by weight of the composition:
  • Antiseptic solutions such as ethyl alcohol and hydrogen peroxide typically evaporate at a rapid rate. For this reason, when antiseptic solutions are used alone, they usually have little to no residual effect.
  • the base oils of the composition namely citrus sinensis, cocos nucifera, and simmondsia chinensis, are effective to trap the antiseptic solution in a pseudo-emulsion antiseptic that remains active for an extended period of time. This allows the composition to have a long lasting antimicrobial and antiviral protection.
  • the base oils also provide antimicrobial, antiviral and antifungal properties.
  • Example 1 demonstrate various combinations of ingredients, including the 3 essential ingredients, which have been observed to yield antimicrobial and antiviral kill rates of 7 log or greater.
  • Example 1 demonstrate various combinations of ingredients, including the 3 essential ingredients, which have been observed to yield antimicrobial and antiviral kill rates of 7 log or greater.
  • Vitamin E 0.3% In use, the antimicrobial and antiviral composition is applied to the skin surface surrounding the opening of the nostrils according to the following instructions:
  • This study was designed to evaluate the persistent antimicrobial efficacy of one (1) test product intended for prevention of airborne illness when applied within the proximal nares (the first 0.25" of a naris) and one (1) control material.
  • Table I presents the statistical summary of the log 10 recovery values with relation to use of the Test Product.
  • Table II presents the Statistical Summary of the log 10 recovery values with relation to use of the Control Material (Sterile Deionized Water)

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne une composition à effet de barrière antimicrobienne et antivirale pour application topique sur les narines antérieures proximales, comprenant une solution antiseptique en combinaison avec Cocos nucifera (huile de noix de coco) et une ou plusieurs huiles d'agrumes telles que, par exemple, Citrus sinensis (huile d'orange). Divers modes de réalisation peuvent également comprendre l'un ou plusieurs des ingrédients additionnels suivants: de l'acide laurique, du d-limonène, de l'huile de soja, de l'huile d'émeu, un extrait de pépins de pamplemousse, du soja de glycine, Simmondsia chinensis (jojoba), Aloe vera et un conservateur tel que du benzoate de sodium, du BHT, du chlorure de benzalkonium et de la vitamine E.
PCT/US2008/011473 2007-10-03 2008-10-02 Composition antimicrobienne et antivirale WO2009045515A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/906,640 US20090011042A1 (en) 2005-07-26 2007-10-03 Antimicrobial and antiviral composition
US11/906,640 2007-10-03
US12/148,967 2008-04-23
US12/148,967 US7638147B2 (en) 2005-07-26 2008-04-23 Antimicrobial and antiviral composition

Publications (3)

Publication Number Publication Date
WO2009045515A2 true WO2009045515A2 (fr) 2009-04-09
WO2009045515A3 WO2009045515A3 (fr) 2009-07-30
WO2009045515A4 WO2009045515A4 (fr) 2009-10-01

Family

ID=40526883

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/011473 WO2009045515A2 (fr) 2007-10-03 2008-10-02 Composition antimicrobienne et antivirale

Country Status (1)

Country Link
WO (1) WO2009045515A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040086575A1 (en) * 2002-11-04 2004-05-06 Smith Jeffrey B. Anti-viral compositions and methods of making and using the anti-viral compositions
US20040166183A1 (en) * 1998-05-20 2004-08-26 Ruseler-Van Embden Johanna G. H. Methods and means for preventing or treating inflammation or pruritis
US20050271595A1 (en) * 2004-06-03 2005-12-08 Brown James S Sanitizing composition and method of preparation
US20060051384A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Antiseptic compositions and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040166183A1 (en) * 1998-05-20 2004-08-26 Ruseler-Van Embden Johanna G. H. Methods and means for preventing or treating inflammation or pruritis
US20040086575A1 (en) * 2002-11-04 2004-05-06 Smith Jeffrey B. Anti-viral compositions and methods of making and using the anti-viral compositions
US20050271595A1 (en) * 2004-06-03 2005-12-08 Brown James S Sanitizing composition and method of preparation
US20060051384A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Antiseptic compositions and methods of use

Also Published As

Publication number Publication date
WO2009045515A4 (fr) 2009-10-01
WO2009045515A3 (fr) 2009-07-30

Similar Documents

Publication Publication Date Title
US8778415B2 (en) Antimicrobial and antiviral composition
US8999406B2 (en) Antimicrobial and antiviral composition
US7638147B2 (en) Antimicrobial and antiviral composition
US6034133A (en) Use of a virucidal hand lotion to prevent the spread of rhinovirus colds
US6165494A (en) Iodine-containing nasal moisturizing saline and mouthwash solutions
US9943561B2 (en) Antimicrobial and antiviral composition
US6171611B1 (en) Iodine-containing nasal moisturizing saline and mouthwash solutions
US9463212B2 (en) Antimicrobial and antiviral composition
CN105504966A (zh) 一种新型平版胶印油墨
US6869623B2 (en) Non-toxic mucosal disinfectant containing isopropyl alcohol, sesame oil, aloe, and lemon oil
US10307452B2 (en) Antimicrobial and antiviral composition
Naureen et al. Prevention of the proliferation of oral pathogens due to prolonged mask use based on α-cyclodextrin and hydroxytyrosol mouthwash.
CN108042420B (zh) 一种用于口腔保健的组合物及其应用
US20120003333A1 (en) Method of Removing Ticks from the Skin and Reducing the Risk of Bites
US6296882B1 (en) Non-toxic mucosal disinfectant containing isopropyl alcohol, sesame oil, and lemon oil
US6875453B2 (en) Non-toxic disinfectant containing a isopropyl alcohol and sesame oil composition with lemon oil and menthol
WO2009045515A2 (fr) Composition antimicrobienne et antivirale
Hiltunen et al. Preventing airborne infection with an intranasal cellulose powder formulation (Nasaleze Travel®)
CN110638910A (zh) 一种具有抗病毒抑菌消炎作用的口气清新剂及其制备方法
US20140106012A1 (en) Compositions and methods useful for treating pediculosis
US11878032B2 (en) Aqueous saline composition, process for the production of same, and use of same
RU2762506C1 (ru) Средство для аппликации полости рта и носа и способ его применения в составе комплексной терапии инфекционно-воспалительных заболеваний носовой и ротовой полости
BR102020016142A2 (pt) Loção antisséptica e hidratante para mãos e face
Pashaie et al. Design and Fabrication of Two-Filter Nano SL Mask to Deal with Covid-19
WO2022123545A1 (fr) Composition de pulvérisation immunitaire à base de plantes à base d'eau et sa méthode de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08834901

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 22-07-2010)

122 Ep: pct application non-entry in european phase

Ref document number: 08834901

Country of ref document: EP

Kind code of ref document: A2